{{Rsnum
|rsid=9332975
|Gene=SRD5A2
|Chromosome=2
|position=31525347
|Orientation=plus
|GMAF=0.1276
|Gene_s=SRD5A2
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 86.7 | 13.3 | 0.0
| HCB | 81.0 | 17.5 | 1.5
| JPT | 73.5 | 22.1 | 4.4
| YRI | 62.6 | 34.7 | 2.7
| ASW | 61.4 | 38.6 | 0.0
| CHB | 81.0 | 17.5 | 1.5
| CHD | 78.9 | 21.1 | 0.0
| GIH | 84.2 | 15.8 | 0.0
| LWK | 66.4 | 30.0 | 3.6
| MEX | 82.8 | 17.2 | 0.0
| MKK | 65.4 | 30.1 | 4.5
| TSI | 72.5 | 25.5 | 2.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=23499746
|Title=SRD5A1 and SRD5A2 are associated with treatment for benign prostatic hyperplasia with the combination of 5α-reductase inhibitors and α-adrenergic receptor antagonists
}}

{{ClinVar
|ALT=C
|CAF=0.8724; 0.1276
|CHROM=2
|CLNACC=RCV000083668.1
|CLNALLE=1
|CLNDBN=not provided
|CLNHGVS=NC_000002.11:g.31750417T>C
|CLNSIG=1
|COMMON=1
|Disease=not provided
|FwdALT=G
|FwdREF=A
|GENEINFO=SRD5A2:6716
|GENE_ID=6716
|GENE_NAME=SRD5A2
|REF=T
|RSPOS=31750417
|Reversed=1
|SAO=0
|SSR=0
|Tags=RV;PM;PMC;SLO;VLD;G5;HD;GNO;KGPhase1;KGPROD;OTHERKG;PH3;LSD
|VC=SNV
|VP=0x050168000000150517100101
|WGT=0
|dbSNPBuildID=119
|rsid=9332975
}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | FTDNA}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}